PRLD Share Price Performance
US$1.52
0.58 (61.36%)
Price US$1.52
Share Pricen/a
Prelude Therapeutics Incorporated Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
PRLD Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Prelude Therapeutics Incorporated Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.47
- 100.00%
- -1,064.50%
- 0%
About PRLD
- Founded
- 2016
- Employees
- 131
- CEO
- WebsiteView website
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company’s CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
